Nephros Inc (NEPH)

[Chickadee]

Quarterly earnings are due soon. We should get very promising news, that will likely give our PPS another boost. Then there's the DOD contract and FDA approvals. Hopefully, NEPH can exceed $3-$5 plus consistently and get themselves back on the AMEX exchange.

From last quarter:

The company generates revenue from product sales, research and development collaborations, and licensing arrangements.

Quarterly revenue increased to $5.0 million from $3.2 million in the comparable year-ago quarter as sales of the company's once-daily tramadol product rose an impressive 76%. The once-daily tramadol product logged in sales of $3.8 million in the first-quarter of 2009, up from $2.2 million in the first-quarter of 2008. Licensing revenue for the recent first-quarter totaled $1.2 million compared to $1.1 million in the same period a year before.

Now that, the company's once-daily tramadol has been launched in the U.S. too, its sales can be expected to grow appreciably, which may ultimately improve its bottom-line results. In addition, the looming FDA decision on depression drug DDS-04A, if positive, is a near term catalyst that could drive Labopharm's share price higher and traders and investors are placing their bets. Will DDS-04A reach the finish line? ...Stay tuned.

http://www.tradingmarkets.com/.site/news/TOP%20STORY/2405208/